GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kainos Medicine Inc (XKRX:284620) » Definitions » Debt-to-Equity

Kainos Medicine (XKRX:284620) Debt-to-Equity : 0.03 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Kainos Medicine Debt-to-Equity?

Kainos Medicine's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩225.6 Mil. Kainos Medicine's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩39.5 Mil. Kainos Medicine's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₩9,457.8 Mil. Kainos Medicine's debt to equity for the quarter that ended in Mar. 2024 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Kainos Medicine's Debt-to-Equity or its related term are showing as below:

XKRX:284620' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03   Med: 0.15   Max: 8.05
Current: 0.03

During the past 7 years, the highest Debt-to-Equity Ratio of Kainos Medicine was 8.05. The lowest was 0.03. And the median was 0.15.

XKRX:284620's Debt-to-Equity is ranked better than
81.84% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs XKRX:284620: 0.03

Kainos Medicine Debt-to-Equity Historical Data

The historical data trend for Kainos Medicine's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kainos Medicine Debt-to-Equity Chart

Kainos Medicine Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial 0.04 0.91 1.19 0.15 0.03

Kainos Medicine Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.30 0.04 0.03 0.03

Competitive Comparison of Kainos Medicine's Debt-to-Equity

For the Biotechnology subindustry, Kainos Medicine's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kainos Medicine's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kainos Medicine's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Kainos Medicine's Debt-to-Equity falls into.



Kainos Medicine Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Kainos Medicine's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Kainos Medicine's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kainos Medicine  (XKRX:284620) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Kainos Medicine Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Kainos Medicine's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Kainos Medicine (XKRX:284620) Business Description

Traded in Other Exchanges
N/A
Address
16, Daewangpangyo-ro 712 beon-gil, 4th Floor, Institut Pasteur Korea, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13488
Kainos Medicine Inc conducts research and develops medicines used to treat brain diseases, cancers, and infectious diseases.

Kainos Medicine (XKRX:284620) Headlines

No Headlines